Abstract
Prior to the discovery of insulin, the major cause of death in the diabetic population was ketoacidosis. Although insulin and improved glycemic control have improved the longevity of diabetic patients, they still suffer from significant morbidity and mortality due to chronic secondary complications. Long standing diabetes leads to structural and functional alterations in both the micro- and macrovasculature. These complications, involving the retina, kidney, and peripheral nerves, as well as cardiovascular system, severely compromise the quality and expectancy of life. Large scale clinical trials have identified hyperglycemia as the key determinant for the development of such complications. Therapeutic modalities have been developed to target glucose-induced alterations, such as protein kinase C activation, augmented polyol pathway activity, non-enzymatic glycation and oxidative stress to ameliorate chronic complications. However, clinical trials targeting these biochemical alterations have failed to show significant beneficial effects. The plethora of biochemical anomalies that govern the development of chronic diabetic complications may therefore be subject to cross-interaction and complex interplays. Studies in both animal and human diabetes have, however, showed alteration of several vasoactive effector molecules such as endothelins. These molecules may be instrumental in mediating diabetes-induced structural and functional deficits at both the early and late stages of the disease. This review will discuss the current mechanistic understanding of chronic diabetic complications and will explore the potential novel therapeutic interventions.
Keywords: Diabetes, aldose reductase, protein kinase C, advanced glycation end products, oxidative stress, endothelin, fibronectin
Current Vascular Pharmacology
Title: Towards Newer Molecular Targets for Chronic Diabetic Complications
Volume: 4 Issue: 1
Author(s): Zia A. Khan, Hana Farhangkhoee and Subrata Chakrabarti
Affiliation:
Keywords: Diabetes, aldose reductase, protein kinase C, advanced glycation end products, oxidative stress, endothelin, fibronectin
Abstract: Prior to the discovery of insulin, the major cause of death in the diabetic population was ketoacidosis. Although insulin and improved glycemic control have improved the longevity of diabetic patients, they still suffer from significant morbidity and mortality due to chronic secondary complications. Long standing diabetes leads to structural and functional alterations in both the micro- and macrovasculature. These complications, involving the retina, kidney, and peripheral nerves, as well as cardiovascular system, severely compromise the quality and expectancy of life. Large scale clinical trials have identified hyperglycemia as the key determinant for the development of such complications. Therapeutic modalities have been developed to target glucose-induced alterations, such as protein kinase C activation, augmented polyol pathway activity, non-enzymatic glycation and oxidative stress to ameliorate chronic complications. However, clinical trials targeting these biochemical alterations have failed to show significant beneficial effects. The plethora of biochemical anomalies that govern the development of chronic diabetic complications may therefore be subject to cross-interaction and complex interplays. Studies in both animal and human diabetes have, however, showed alteration of several vasoactive effector molecules such as endothelins. These molecules may be instrumental in mediating diabetes-induced structural and functional deficits at both the early and late stages of the disease. This review will discuss the current mechanistic understanding of chronic diabetic complications and will explore the potential novel therapeutic interventions.
Export Options
About this article
Cite this article as:
Khan A. Zia, Farhangkhoee Hana and Chakrabarti Subrata, Towards Newer Molecular Targets for Chronic Diabetic Complications, Current Vascular Pharmacology 2006; 4 (1) . https://dx.doi.org/10.2174/157016106775203081
DOI https://dx.doi.org/10.2174/157016106775203081 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
"New Frontiers in Cardiovascular and Hematologic Disease Treatment: Exploring and Applying Natural Drug Targets"
Cardiovascular and hematologic diseases are among the most pressing global health challenges, placing a heavy burden on public health systems worldwide. As research progresses, novel therapeutic targets continue to be identified, offering new possibilities for treating these complex conditions. However, despite advancements in current therapies, more integrated research approaches are ...read more
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Plant- and Nutraceutical-based Approach for the Management of Diabetes and its Neurological Complications: A Narrative Review
Current Pharmaceutical Design Integrins Modulate Cellular Fibrogenesis at Multiple Levels: Regulation of TGF-β Signaling
Endocrine, Metabolic & Immune Disorders - Drug Targets Phosphate Homeostasis and Disorders of Phosphate Metabolism
Current Pediatric Reviews Amiodarone-Induced SIADH: Two Cases Report
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Natural Killer T Cells in Atherosclerosis
Current Immunology Reviews (Discontinued) Roles of p38-MAPK in Insulin Resistant Heart: Evidence from Bench to Future Bedside Application
Current Pharmaceutical Design Progranulin, a New Adipokine at the Crossroads of Metabolic Syndrome, Diabetes, Dyslipidemia and Hypertension
Current Pharmaceutical Design Can Diabetes Heal?- From Observations to Perspectives
Current Diabetes Reviews Anti-VEGF Treatment and Response in Age-related Macular Degeneration: Disease’s Susceptibility, Pharmacogenetics and Pharmacokinetics
Current Medicinal Chemistry Gadolinium-Contrast Toxicity in Patients with Kidney Disease: Nephrotoxicity and Nephrogenic Systemic Fibrosis
Current Drug Safety Update on the Cardiac Safety of Moxifloxacin
Current Drug Safety Review of Pediatric Uveitis
Current Pediatric Reviews Vascular Endothelial Growth Factor Electro-Gene Therapy Improves Functional Outcome in a Mouse Model of ALS
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Amylin Replacement With Pramlintide as an Adjunct to Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: A Physiological Approach Toward Improved Metabolic Control
Current Pharmaceutical Design The Role of 3D Pharmacophore Mapping Based Virtual Screening for Identification of Novel Anticancer Agents: An Overview
Current Topics in Medicinal Chemistry Central Nervous System Involvement in Pediatric Rheumatic Diseases: Current Concepts in Treatment
Current Pharmaceutical Design Interleukin-18: A Proinflammatory Cytokine in HIV-1 Infection
Current HIV Research Venous Thromboembolism Following Major Abdominal Surgery for Cancer: A Guide for the Surgical Intern
Current Pharmaceutical Design Assessment of Cardiac Safety for PPARγ Agonists in Rodent Models of Heart Failure: A Translational Medicine Perspective
Current Molecular Pharmacology The Angiotensin Type 1 Receptor: A Drug Target to Reduce the Risk of Organ Transplant Rejection
Letters in Drug Design & Discovery